<a href="https://www.fiercebiotech.com/biotech/bioage-ceo-talks-nlrp3-and-pipeline-pill-ambitions" hreflang="en">BioAge CEO talks NLRP3 and ‘pipeline in a pill’ ambitions</a>
fiercebiotech.com·May 22, 2026
In this episode of "The Top Line," BioAge CEO Kristen Fortney discusses the company's focus on aging biology and inflammation, highlighting the potential of their oral NLRP3 inhibitor for treating various diseases.
For someone tracking biotech and AI drug discovery, the key insight is that BioAge's development of an oral NLRP3 inhibitor, discussed by CEO Kristen Fortney, represents a promising multi-disease therapeutic approach targeting aging biology and inflammation. This could signal an opportunity for investment or collaboration in the development of versatile therapeutics that can address multiple age-related diseases simultaneously.